Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 7/20 | 0.48 |
| ▸ | HTR3B | O95264 | 7/20 | 0.48 |
| ▸ | HTR3A | P46098 | 7/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 7/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 7/20 | 0.48 |
| ▸ | PLAU | P00749 | 5/20 | 0.47 |
| ▸ | SLC22A2 | O15244 | 3/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.47 |
| ▸ | SLC22A3 | O75751 | 3/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228888 | 0.88 | HTR3E (0.59) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL6034160 | 0.82 | PLAU (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL5471239 | 0.81 | HTR3E (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL3250038 | 0.80 | HTR3E (0.48) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL7813484 | 0.80 | HTR3E (0.77) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL1368 | 0.80 | HTR3E (0.72) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL2862598 | 0.80 | HTR3E (0.77) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL5733225 | 0.80 | HTR3E (0.79) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL6034777 | 0.79 | PLAU (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL4613845 | 0.79 | PLAU (0.73) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067409-B2 | Protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2222682-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009070516-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-06-04 | — | — | WO | disclosed |
| EP-1187816-B1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMTIED | 2004-09-16 | — | — | US | disclosed |
| US-6579983-B1 | Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase | CELLTECH R&D LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| EP-1187816-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078731-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | HTR3E 3347/4885HTR3B 2833/4885HTR3A 3560/4885 |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | HTR3E 1499/4885HTR3B 1512/4885HTR3A 664/4885 |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | HTR3E 1249/4885HTR3B 1267/4885HTR3A 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.